


Tulmimetostat

Cat. No.:	HY-145602
CAS No.:	2567686-02-4
Molecular Formula:	C ₂₈ H ₃₆ ClN ₃ O ₅ S
Molecular Weight:	562.12
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme. Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies ^{[1][2][3][4]} .	
IC₅₀ & Target	EZH2	EZH1
In Vitro	Tulmimetostat is sensitive to AR-dependent prostate cancer cell lines (including LNCaP, 22Rv1, and VCaP) and AR-dependent cell line-derived transplanted tumor (CDX) and patient-derived transplanted tumor (PDX) models ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Tulmimetostat has a synergistic effect on Enzalutamide (HY-70002) in prostate cancer CDX and PDX models, overcoming anti-androgen resistance induced by AR changes and enhancing tumor growth inhibition ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Drescher C, et al. EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC) 2023.
- [2]. Morschhauser F, et al. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Rev. 2022 Nov;56:100988.
- [3]. Qiu J, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12(15):1415-1430.
- [4]. Rentian Wu, et al. Abstract 2126: Therapeutic potential of CPI-0209. Cancer Res 1 July 2021; 81 (13_Supplement): 2126.
- [5]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA